Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study

Author:

Gupta SudeepORCID,Biswas Ghanashyam,Babu Suresh,Maksud Tanveer M.,Lakshmaiah Kuntegowdennahalli C.,Patel Jayanti G.,Raja GopalORCID,Boya Rakesh R.,Patil Pramod,Choudhury Kakali,Bondarde Shailesh A.,Neve Rakesh S.,Bhat Guruprasad,Mamillapalli Gopichand,Patel Apurva A.,Patel PiyushORCID,Joshi Nisarg,Bajaj Vinay,Khan Mujtaba A.ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference26 articles.

1. Chemotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer: an overview;Andreopoulou;Curr Breast Cancer Rep,2013

2. Chemotherapy for metastatic breast cancer;Barni;Ann Oncol,2005

3. Drug resistance and the role of combination chemotherapy in improving patient outcomes;Yardley;Int J Breast Cancer,2013

4. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy;Zhang;Proc Natl Acad Sci U S A,2017

5. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study;Wang;Cancer Chemother Pharmacol,2012

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3